Literature DB >> 25117104

A cooperative approach to diagnosis of rare diseases: primitive myxoid mesenchymal tumor of infancy.

David W Cuthbertson1, Kevin Caceres2, John Hicks3, Ellen M Friedman4.   

Abstract

Primitive Myxoid Mesenchymal Tumor of Infancy (PMMTI) is a recently recognized locally aggressive myofibroblastic tumor. It is a low- to intermediate-grade fibroblastic malignancy with a high local recurrence rate but low metastatic potential and is composed of primitive spindled cells in a myxoid background. We present the eleventh reported case of PMMTI, occurring in the sinonasal tract of a 3-year old child. This case is novel in both the relatively older age of the child, the location of the tumor, and the role that immunohistochemical stains, and cytogenetic analysis played in differentiating it from similar diagnoses that differ considerably in their chemosensitivity and recurrence rates. Close collaboration between the pathologist and surgeon was crucial as different diagnoses would have led to vastly different treatment strategies for the patient.
© 2014 by the Association of Clinical Scientists, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 25117104

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  3 in total

1.  Primitive myxoid mesenchymal tumor of infancy with brain metastasis: first reported case.

Authors:  Amna Afzal Saeed; Quratulain Riaz; Nasir Ud Din; Sadaf Altaf
Journal:  Childs Nerv Syst       Date:  2018-09-03       Impact factor: 1.475

2.  Recurrent BCOR internal tandem duplication and BCOR or BCL6 expression distinguish primitive myxoid mesenchymal tumor of infancy from congenital infantile fibrosarcoma.

Authors:  Teresa Santiago; Michael R Clay; Sariah J Allen; Brent A Orr
Journal:  Mod Pathol       Date:  2017-03-03       Impact factor: 7.842

Review 3.  BCOR involvement in cancer.

Authors:  Annalisa Astolfi; Michele Fiore; Fraia Melchionda; Valentina Indio; Salvatore N Bertuccio; Andrea Pession
Journal:  Epigenomics       Date:  2019-05-31       Impact factor: 4.778

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.